Company intelligence / Profile preview

Exazyme

Berlin, Berlin, Germanyexazyme.com ↗

Ownership: Private
Development stage: Commercial

Overview

Exazyme has demonstrated the ability of its AI-driven platform to engineer proteins with superior performance using far fewer experiments than traditional approaches. In collaboration with Max Planck Institute researchers, they developed novel enzymes that doubled carboxylation rates while reducing energy demand by 60% in synthetic photorespiration bypass pathways—outperforming existing methods for CO₂ fixation.

Therapeutic areas: Other
Modalities: Protein engineering/design (enabling technology for biologics, enzymes, biocatalysts)AI-driven protein optimization
Industry: Non-Drug Biotech

Partnerships

Collaboration with Max Planck Institute on enzyme engineering projects related to synthetic biology and carbon capture/fixation pathways.

Beyond the preview

Go deeper on Exazyme.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exazyme.

Explore the full profile